The ADSs are listed on the Nasdaq Global Select Market

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by Molecular Partners AG of 3,642,988 American depositary shares (ADSs), representing 3,642,988 of its ordinary shares. Molecular Partners’ ADSs are listed on the Nasdaq Global Select Market under the symbol “MOLN” and its ordinary shares are listed on the SIX Swiss Exchange under the symbol “MOLN.”

Headquartered in Schlieren, Switzerland, Molecular Partners is a clinical stage biopharmaceutical company applying its pioneering DARPin product candidates to treat serious diseases, with a current focus on infectious disease, oncology and ophthalmology.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate Samuel S. Vallejo. Partner David R. Bauer and associate Shreya R. Kundur provided intellectual property advice. The tax team included counsel Liang Zhang and associate Alanna Phillips. All members of the Davis Polk team are based in the New York office.

Copy link to share post